Magdalena Madero1, Mark J Sarnak. 1. Division of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, México City, Mexico.
Abstract
PURPOSE OF REVIEW: To discuss recent studies which have evaluated determinants of cystatin C and to focus on the relationship of cystatin C with mortality, cardiovascular disease (CVD), and noncardiovascular outcomes. RECENT FINDINGS: In the Chronic Kidney Disease Epidemiology Study cystatin C was associated with demographic characteristics independent of measured glomerular filtration rate (GFR), although this was to a smaller extent than creatinine. In patients with established chronic kidney disease (CKD), cystatin C was strongly and inversely correlated with measured GFR, suggesting that although cystatin C may have other determinants, it is primarily a measure of kidney function. Several cohort studies, particularly in older adults, have now demonstrated that cystatin C is linearly associated with mortality, CVD and non-CVD outcomes, whereas creatinine is primarily associated with risk in individuals with more advanced kidney disease. A recent study has also shown that changes in kidney function as ascertained by cystatin C, even within the relatively normal range, are associated with subsequent CVD and all-cause mortality among older adults. SUMMARY: Cystatin C appears to capture an association of mild kidney disease with increased risk of mortality, CVD and non-CVD outcomes. Future studies should evaluate whether cystatin C can improve medical decision-making and lead to favorable patient outcomes.
PURPOSE OF REVIEW: To discuss recent studies which have evaluated determinants of cystatin C and to focus on the relationship of cystatin C with mortality, cardiovascular disease (CVD), and noncardiovascular outcomes. RECENT FINDINGS: In the Chronic Kidney Disease Epidemiology Study cystatin C was associated with demographic characteristics independent of measured glomerular filtration rate (GFR), although this was to a smaller extent than creatinine. In patients with established chronic kidney disease (CKD), cystatin C was strongly and inversely correlated with measured GFR, suggesting that although cystatin C may have other determinants, it is primarily a measure of kidney function. Several cohort studies, particularly in older adults, have now demonstrated that cystatin C is linearly associated with mortality, CVD and non-CVD outcomes, whereas creatinine is primarily associated with risk in individuals with more advanced kidney disease. A recent study has also shown that changes in kidney function as ascertained by cystatin C, even within the relatively normal range, are associated with subsequent CVD and all-cause mortality among older adults. SUMMARY:Cystatin C appears to capture an association of mild kidney disease with increased risk of mortality, CVD and non-CVD outcomes. Future studies should evaluate whether cystatin C can improve medical decision-making and lead to favorable patient outcomes.
Authors: G W Small; P V Rabins; P P Barry; N S Buckholtz; S T DeKosky; S H Ferris; S I Finkel; L P Gwyther; Z S Khachaturian; B D Lebowitz; T D McRae; J C Morris; F Oakley; L S Schneider; J E Streim; T Sunderland; L A Teri; L E Tune Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Michael G Shlipak; Ronit Katz; Linda F Fried; Nancy Swords Jenny; Catherine O Stehman-Breen; Anne B Newman; David Siscovick; Bruce M Psaty; Mark J Sarnak Journal: J Am Coll Cardiol Date: 2005-01-18 Impact factor: 24.094
Authors: Mark J Sarnak; Ronit Katz; Catherine O Stehman-Breen; Linda F Fried; Nancy Swords Jenny; Bruce M Psaty; Anne B Newman; David Siscovick; Michael G Shlipak Journal: Ann Intern Med Date: 2005-04-05 Impact factor: 25.391
Authors: Eric L Knight; Jacobien C Verhave; Donna Spiegelman; Hans L Hillege; Dick de Zeeuw; Gary C Curhan; Paul E de Jong Journal: Kidney Int Date: 2004-04 Impact factor: 10.612
Authors: Tomas Jernberg; Bertil Lindahl; Stefan James; Anders Larsson; Lars-Olof Hansson; Lars Wallentin Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: R Lertnawapan; A Bian; Y H Rho; P Raggi; A Oeser; J F Solus; T Gebretsadik; A Shintani; C M Stein Journal: Lupus Date: 2011-11-09 Impact factor: 2.911
Authors: Jason L Sanders; Robert M Boudreau; Linda P Fried; Jeremy D Walston; Tamara B Harris; Anne B Newman Journal: J Am Geriatr Soc Date: 2011-08-24 Impact factor: 5.562
Authors: Nrupen A Bhavsar; Lawrence J Appel; John W Kusek; Gabriel Contreras; George Bakris; Josef Coresh; Brad C Astor Journal: Am J Kidney Dis Date: 2011-09-22 Impact factor: 8.860
Authors: Mario Riverol; James T Becker; Oscar L López; Cyrus A Raji; Paul M Thompson; Owen T Carmichael; H Michael Gach; William T Longstreth; Linda Fried; Russell P Tracy; Lewis H Kuller Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472